Skip to main content

17-02-2020 | GLP-1 agonists | News

News in brief

Novel drug combination shows preclinical diabetes promise

Eleanor McDermid

medwireNews: Combining a glucagon-like peptide (GLP)-1 receptor agonist with an experimental compound could increase the function and numbers of beta cells, suggest preclinical findings in Science Translational Medicine.

The researchers tested drugs from the dual-specificity tyrosine phosphorylation–regulated kinase 1A (DYRK1A) inhibitor class, which have been shown to induce cell proliferation, in combination with various GLP-1 receptor agonists to provide beta-cell specificity.

They found the combination to have dose-dependent synergistic effects on beta cells from deceased donors, with the DYRK1A inhibitors having little or no effect alone, but showing a marked effect on beta-cell proliferation when given with “even trivial doses” of a GLP-1 receptor agonist. This was the case for all combinations tested, and the increased proliferation did not lead to dedifferentiation of the beta cells.

The drug combination caused proliferation of human beta cells when transplanted into mice, and normalized blood glucose in mice that received human beta cells following the obliteration of their own islets.

The proliferation induced by the drug combination “may be in a range that could allow for restoration of normal β cell mass in people with [type 2 diabetes] and [type 1 diabetes],” say Andrew Stewart (Icahn School of Medicine at Mount Sinai, New York, USA) and study co-authors.

They note, however, that many barriers remain to clinical use, including the possibility of DYRK1A inhibitors having psychoactive properties, and the potential for oncogenic effects of regenerative therapies, such as this drug combination.

medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group

Sci Transl Med 2020; 12: eaaw9996

ESC Congress 2021 coverage

27 – 30 August: Browse all of the latest coverage

Addressing suicide risk in diabetes

14-07-2021 | Mental health | Feature | Article

Suicide in diabetes: An important but under-recorded problem

How frequent are suicide deaths in people with diabetes, and can the data be trusted?

14-07-2021 | Mental health | Feature | Article

Risk for suicidal ideation: Who, when, and why?

What makes some people more likely than others to have suicidal thoughts? We outline the risk factors and circumstances that can play a role.

14-07-2021 | Mental health | Feature | Article

Creating a safety net: How doctors can help suicidal patients

Screening, emergency protocols, and person-centered care – just some of the ways healthcare professionals can identify and support people at increased risk for suicide. Click through for more.

Suicide risk in diabetes: Why doctors may hesitate to screen, but should not